Rexahn Pharmaceuticals to Present at Two Upcoming Conferences
B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on March 16
Oppenheimer 28th Annual Healthcare Conference on March 21
ROCKVILLE, Md., March 13, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced the Company will present at two upcoming conferences in March.
Peter D. Suzdak, chief executive officer of Rexahn will present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) on Friday, March 16, 2018. The conference will be held March 15-17, 2018 at the Intercontinental Hotel in Hangzhou, China. CHIPS is focused on building cross-border relationships between Chinese and Western Healthcare investors and companies.
Douglas J. Swirsky, president and chief financial officer of Rexahn will present at the Oppenheimer 28th Annual Healthcare Conference on March 21, 2018 at 2:10 p.m. EDT. The conference is taking place on March 20-21, 2018 at the Westin New York Grand Central in New York City.
Rexahn’s presentations at these two conferences will not be webcast, however a copy of the Company’s March 2018 corporate overview presentation, which will be utilized for these two conferences, can be found on the investor relations section of the Company's website at http://investors.rexahn.com.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. The Company's mission is to improve the lives of cancer patients by developing next generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Pre-clinical studies show that certain of Rexahn's product candidates may be effective against multiple types of cancer, including drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development including RX-0201. For more information about the Company and its oncology programs, please visit www.rexahn.com.
LifeSci Advisors, LLC
Released March 13, 2018